|Time Commitment:||3.5 hours over 6 weeks|
|Target Professions:||DO, MD, Physician Assistant, Diabetes Educator|
|Target Specialties:||Diabetology, Endocrinology, Family Medicine, Internal Medicine|
|Credits Available:||3.5 AMA PRA Category 1 Credits™ for physicians; 3.5 ANCC Contact Hours for nurses and nurse practitioners|
This curriculum focuses on improving outcomes for patients with T2DM who are likely to benefit from the addition of a newer insulin, such as an MTI, to their therapeutic regimen and improving the delivery of telehealth services to underserved patients with T2DM via a multidisciplinary team approach.
This assessment will provide a baseline measure of your knowledge of use of meal-time insulin in patients with T2DM.
Learn more about the appropriate use of faster-acting insulin for patients with poorly controlled T2DM.
Join 2 expert faculty as they explore strategies for initiating faster-acting insulins in patients with T2DM.
Explore best practices for the use of telemedicine for patients with diabetes.
This is a continuation of the case presented in Module 1
This post-activity assessment will ascertain the knowledge gained as a result of your participation in this initiative.
The purpose of this discussion is to review key concepts presented during the individual program modules; reflect on new information and potential implications for and application in routine practice; and engage in a discussion of specific, persistent gaps.
The purpose of this discussion is to review a complex patient case and discuss critical points for clinical interventions within the case. Learners will have the opportunity to share their experiences in treating such a patient within their own practice, and to solicit feedback from the group.
This activity features a 47-year old non-Hispanic Caucasian male who presents to your clinic today with symptoms of uncontrolled type 2 diabetes.
In light of the information reviewed and discussed during this program, can you share an action plan that you will implement to improve the outcomes for your patients with diabetes who are candidates for mealtime insulin.